Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents

A cellular, cytostatic technology used in the field of treatment of cancer or viral diseases that can address issues such as reduced therapeutic viability of the immune system

Inactive Publication Date: 2001-11-28
MAXIM PHARMA INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0031] Therapeutic viability of several immune cell-stimulating compounds now promising to be effective anticancer and antiviral agents is reduced by negative regulation of the immune system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents
  • Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents
  • Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0102] Isolated peripheral blood lymphocytes were cultured at 37° C. for 16 hours in microplates with or without their own MO (150,000 cells / well / total volume 0.2 ml). Simultaneously with T cell activation compounds such as IFN-α (100U / ml) or IL-2 (100U / ml), H 2 Cells were treated with receptor agonists such as histamine (50 [mu]M) or media controls. After the culture was completed, the cells were rinsed twice and incubated with labeled monoclonal antibodies, which were antibodies against T cell surface markers CD3ε, CD4, CD8 and CD69 or NK cell marker CD56 (purchased from Becton Dickinson, stockholm, Sweden). Expression of the different antigens (according to forward scatter and side scatter light) was estimated by lymphocyte gating and compared to the pure lymphocyte fraction (comprising + / 4 + , CD3e + / 8 + and CD3E + / 8 + / 56 + .

[0103] unstimulated CD3ε + CD69 expression on the surface of T cells was very low (~2%). In the absence of MO, after treatment with IL...

Embodiment 2

[0109] In this example, elutriated lymphocytes were incubated with MO as described in Example 1 for 16 hours at 37°C. Add catalase at 10-200U / ml. That is, hydrogen peroxide scavenger. IL-2 was added at 100 U / ml. Monitoring CD3ε by flow cytometry + CD69 expression of T cells. Data represent CD3ε + Mean expression of CD69 in lymphocytes±s.e.m.

[0110] It was found that catalase significantly reversed the inhibitory effect of MO on cytokine-induced CD69 expression (Figure 4), but did not affect the induction of CD69 expression in each cell in the absence of MO. Use catalase alone at concentrations ranging from 0 to 200 U / ml for CD3ε expressing the CD69 marker + Cell percentage has little effect. However, catalase had a greater effect on CD69 expression in the presence of IL-2. More specifically, the data show that with IL-2 treatment alone in the absence of catalase, only a little more than 4% of processed CD3ε + Cells exhibit CD69 labeling. However, as the catalase co...

Embodiment 3

[0113] In order to explore the H 2 Effect of receptor agonists on MO-induced inhibition of T cell activation based on CD69 expression, CD3ε incubated with MO at 37°C + T cells for 16 hours, and with IFN-α (100U / ml), IL-2 (100U / ml), culture medium, H 2 Agonists (histamine) and / or H 2 Receptor antagonist (ranitidine) treatment.

[0114] The effect of histamine on cytokine-induced CD69 expression is dose-dependent, the final concentration of histamine is 0.1-50μM, ED 50 about 2 μM. ranitidine i.e. H 2 A type of histamine receptor antagonist that completely antagonizes the effects of histamine at equimolar or 10-fold lower concentrations. Similar concentrations of AH20399AA did not block the histamine effect. AH20399AA is a chemical reference substance of ranitidine whose thioester group is replaced by an ester group, so it is the same as H 2 Receptor affinity is reduced >50-fold (Hellstrand, K., et al., J. leukoc. Biol. 55:392 (1994)).

[0115] The results of this example ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for facilitating activation of T-cells in a patient, comprising: identifying a patient in need of enhanced T-cell activity, administering an effective amount of a T-cell activating composition to the patient, and administering an effective amount of a compound that inhibits the production or release of intercellular reactive oxygen metabolites to the patient. The present invention further relates to the use of H2-receptor agonists to augment the effectiveness of vaccines.

Description

field of invention [0001] The present invention relates to a method for the treatment of cancer or viral diseases wherein histamine or H 2 Receptor agonists or in combination with other agents. Administration of different agents not only activated T cells from the deleterious and suppressive effects of monocytes / macrophages (MO), but also stimulated the anticancer and antiviral properties of T cells. In addition, as histamine or H 2 As a direct effect of receptor agonists, antigen-presenting cells will be more efficient at presenting antigen to T cells. It is also contemplated that preferably in a synergistic manner with H 2 In combination with other T cell activators, the receptor agonist stimulates the cytotoxic activity of cytotoxic T cells (CTLs) and other T cell activities. Representatives of such immunostimulatory compounds include cytokines, peptides, flavonoids, vaccines and vaccine adjuvants. Other classes of agents that can be used with the methods of the invent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/13A61K31/137A61K31/138A61K31/166A61K31/17A61K31/196A61K31/198A61K31/255A61K31/352A61K31/4045A61K31/407A61K31/4166A61K31/4168A61K31/4172A61K31/475A61K31/513A61K31/519A61K31/52A61K31/522A61K31/525A61K31/5513A61K31/662A61K31/704A61K31/7048A61K31/7068A61K31/7072A61K31/7076A61K31/708A61K31/7135A61K33/24A61K35/12A61K38/00A61K38/20A61K38/21A61K39/00A61K39/04A61K39/106A61K39/145A61K39/21A61K39/265A61K39/29A61K39/39A61K45/00A61K45/06A61P31/12A61P35/00A61P37/04
CPCA61K2035/124A61K2039/55511A61K45/06A61K38/212A61K2039/515A61K31/352A61K38/2013A61K39/39A61P31/12A61P35/00A61P37/04Y02A50/30A61K39/00
Inventor K·赫尔斯特兰德S·赫尔莫德松K·R·格尔森
Owner MAXIM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com